Whole transcriptome expression assays have provided a detailed characterization of breast cancer subtypes. These subtypes are currently being utilized to provide clinically relevant prognostic information at the time of diagnosis. Application of this knowledge is currently being incorporated into clinical trials in order to provide therapeutic information. The seminar will focus on the development of the foundational clinical test for subtype, as well as ongoing work in toward development of clinically relevant biomarkers.